Amedisys Inc., trading under the symbol AMED, has completed its merger with UnitedHealth Group Incorporated. This transaction, approved by Amedisys shareholders on September 8, 2023, officially closed on August 14, 2025. The common stock of Amedisys will have its last trading day on August 14, 2025, with trading suspension effective August 15, 2025. Shareholders will receive $101.00 for each share they held. The CUSIP number for Amedisys Inc. Common Stock is 023436108.

Original article (merger)

Actionable Information: The article provides actionable information for Amedisys shareholders. They can expect to receive $101.00 per share. The last day to trade Amedisys stock (AMED) is August 14, 2025, with trading suspension starting August 15, 2025. This allows shareholders to make decisions about their holdings before the suspension.

Educational Depth: The article offers basic factual information about a corporate merger. It states the companies involved, the approval date, the closing date, and the per-share payout. However, it lacks educational depth as it does not explain the reasons behind the merger, the implications for employees or patients, or the broader impact on the healthcare industry.

Personal Relevance: This information is highly relevant to Amedisys shareholders. It directly impacts their investments by detailing the terms of the merger, the value they will receive for their shares, and the timeline for these changes. For individuals who are not shareholders, the personal relevance is minimal.

Public Service Function: The article serves a limited public service function by disseminating important financial news to shareholders. It provides key dates and financial details related to a significant corporate event. However, it does not offer broader public safety advice, emergency contacts, or tools for the general public.

Practicality of Advice: The information provided is practical for Amedisys shareholders. They know the exact amount they will receive per share and the critical dates for trading their stock. This allows them to plan accordingly.

Long-Term Impact: For Amedisys shareholders, this information has a direct long-term financial impact as it signifies the end of their investment in Amedisys and the realization of a specific payout. For others, the long-term impact is indirect, potentially related to changes in the healthcare landscape due to the merger.

Emotional or Psychological Impact: For Amedisys shareholders, this news could evoke a range of emotions, from satisfaction at receiving a payout to potential uncertainty about future investments. However, the article itself is purely factual and does not aim to influence emotions.

Clickbait or Ad-Driven Words: The article does not use clickbait or ad-driven language. It presents factual information in a straightforward manner.

Missed Chances to Teach or Guide: The article missed opportunities to provide more comprehensive guidance. For instance, it could have suggested that shareholders consult with a financial advisor to discuss reinvestment strategies after receiving their payout. It could also have provided links to official company statements or regulatory filings for further details on the merger's implications. A normal person could find better information by visiting the investor relations sections of both Amedisys and UnitedHealth Group's websites, or by consulting financial news outlets that offer more in-depth analysis of mergers and acquisitions.

The text uses a neutral tone to present factual information about a business merger. It states that Amedisys Inc. merged with UnitedHealth Group Incorporated. The text provides specific dates for shareholder approval and the official closing of the transaction. It also details the last trading day and suspension of Amedisys stock, along with the price shareholders will receive. The CUSIP number is also included for identification.

The provided text about Amedisys Inc.'s merger with UnitedHealth Group Incorporated is largely factual and neutral, aiming to inform rather than evoke strong emotions. However, a subtle sense of finality and transition can be perceived. The phrase "completed its merger" and "officially closed" suggests a sense of accomplishment and a definitive end to a process. This might be interpreted as a mild form of satisfaction or relief for those involved in the transaction, as it marks the successful conclusion of a significant business undertaking. The purpose of this tone is to convey certainty and closure to shareholders and interested parties, building trust by presenting the information as a resolved event.

The text guides the reader's reaction by providing clear, factual details about the merger's timeline and financial outcome. The mention of shareholders receiving "$101.00 for each share they held" is a key piece of information that directly impacts the reader's financial understanding of the event. This detail is presented factually, but its implication is positive for shareholders, suggesting a successful financial outcome for their investment. The writer uses straightforward language to avoid ambiguity, which helps to build confidence in the information being shared. There are no overt emotional appeals or persuasive techniques like storytelling or exaggeration. Instead, the message relies on the clarity of the facts to convey the significance of the merger and its implications for Amedisys shareholders. The directness of the information, such as the specific dates and the price per share, serves to inform and confirm, rather than to manipulate or sway opinion through emotional means. The overall effect is one of clear communication about a significant business change.